Introduction Major cardiac events are known to be reduced in patients with acute coronary syndrome by an association of aspirin with clopidogrel (1)(2). In cardiac surgery as well, aspirin treatment has been shown to reduce major cardio-vascular events and mortality in postoperative period after coronary artery bypass grafting (CABG) without any increase of postoperative bleeding (3)(4). In a recent study performed in our department, Ouattara and al. have shown in cardiac surgery that the combination of aspirin with clopidogrel does not increase postoperative bleeding, transfusion or surgical reexploration after CABG when aprotinin is used during surgery, by comparison to aspirin alone (5). In conclusion, the authors suggested no disruption of aspirin and clopidogrel when patients are treated with this association before surgery. Unfortunately, since the trials of Mangano and al. (6) and of the BART investigators (7), aprotinin, a plasmin inhibitor derived from bovine lung tissues, has been withdrawn for safety reasons. Therefore, physicians are restrained to use instead tranexamic acid, a synthetic molecule that inhibits conversion of the inactive plasminogen to plasmin, to minimize bleeding and to reduce exposure to blood products.